Sickle cell disease, vasculopathy, and therapeutics

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 451-466

  Kassim, Adetola A ^a   DeBaun, Michael R ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

pulmonary hypertension; retinopathy; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ATORVASTATIN; BEVACIZUMAB; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; MEVINOLIN; NITRIC OXIDE; PADGEM PROTEIN; PROSTACYCLIN; SILDENAFIL; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ACUTE CHEST SYNDROME; ARTERIOVENOUS FISTULA; ARTERY THROMBOSIS; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; BONE MARROW TRANSPLANTATION; BONE NECROSIS; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHELATION; CHEMOPROPHYLAXIS; CHRONIC KIDNEY DISEASE; CRYOTHERAPY; DIABETIC RETINOPATHY; DIATHERMY; EPIRETINAL MEMBRANE; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HEMOGLOBINOPATHY; HUMAN; INTRAVASCULAR HEMOLYSIS; KIDNEY DISEASE; KIDNEY FAILURE; LASER COAGULATION; LEG ULCER; LEUKOCYTE ADHERENCE; LEUKOCYTE AGGREGATION; MACROALBUMINURIA; MAGNETIC RESONANCE ANGIOGRAPHY; MEMBRANOUS GLOMERULONEPHRITIS; MICROALBUMINURIA; MOYAMOYA DISEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PHLEBOTOMY; PRIAPISM; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN POLYMERIZATION; PROTEINURIA; PULMONARY HYPERTENSION; RENOVASCULAR DISEASE; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE; VITREOUS HEMORRHAGE;

ANEMIA, SICKLE CELL; DNA; GENETIC THERAPY; HEMOGLOBIN, SICKLE; HUMANS; MUTATION; OXIDATIVE STRESS; VASCULAR DISEASES;

EID: 84873054127     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-120611-143127     Document Type: Review

References (112)

1. Bunn HF, Forget BG, Ranney HM. 1997. Hemoglobinopathies. Major Probl. Intern. Med. 12:1-291
2. Steinberg MH. 2001. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge and New York: Cambridge Univ. Press. xiv, 1268 pp.
3. Granger DN, Korthuis RJ. 1995. Physiologic mechanisms of postischemic tissue injury. Annu. Rev. Physiol. 57:311-32
4. Ballas SK. 1991. Sickle cell anemia with few painful crises is characterized by decreased red cell deformability and increased number of dense cells. Am. J. Hematol. 36(2):122-30
5. Gladwin MT, Sachdev V, Jison ML, et al. 2004. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med. 350(9):886-95
6. Reiter CD, WangX, Tanus-Santos JE, et al. 2002. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8(12):1383-89
7. Kato GJ, Gladwin MT, Steinberg MH. 2007. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 21(1):37-47
8. Hebbel RP. 2011. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-basedmedicine. Am. J.Hematol. 86(2):123-54
9. Bunn HF, Nathan DG, Dover GJ, et al. 2010. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 116(5):687-92
10. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. 1998. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91(1):288-94
11. Powars D, Wilson B, Imbus C, et al. 1978. The natural history of stroke in sickle cell disease. Am. J. Med. 65(3):461-71
12. Powars DR, Chan LS, Hiti A, et al. 2005. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore) 84(6):363-7611.
13. Bernaudin F, Verlhac S, Arnaud C, et al. 2011. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 117(4):1130-40; quiz 1436
14. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. 2012. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 119(16):3684-90
15. DeBaun MR, Armstrong FD, McKinstry RC, et al. 2012. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 119(20):4587-96
16. Lee MT, Piomelli S, Granger S, et al. 2006. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 108(3):847-52
17. Adams RJ, McKie VC, Carl EM, et al. 1997. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann. Neurol. 42(5):699-704
18. Adams R, McKie V, Nichols F, et al. 1992. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N. Engl. J. Med. 326(9):605-10
19. ValadiN, Silva GS, Bowman LS, et al. 2006. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology 67(4):572-74
20. Moser FG, Miller ST, Bello JA, et al. 1996. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. Am. J. Neuroradiol. 17(5):965-72
21. Pegelow CH, Macklin EA, Moser FG, et al. 2002. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 99(8):3014-18
22. Steen RG, Emudianughe T, Hankins GM, et al. 2003. Brain imaging findings in pediatric patients with sickle cell disease. Radiology 228(1):216-25
23. Serjeant GR, Serjeant BE. 2001. Sickle Cell Disease. Oxford and New York: Oxford Univ. Press. xix, 772 pp. 3rd ed.
24. Merkel KH, Ginsberg PL, Parker JC Jr, et al. 1978. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke 9(1):45-52
25. Pegelow CH, Wang W, Granger S, et al. 2001. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch. Neurol. 58(12):2017-21
26. Rothman SM, Fulling KH, Nelson JS. 1986. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann. Neurol. 20(6):684-90
27. Pavlakis SG, Bello J, Prohovnik I, et al. 1988. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann. Neurol. 23(2):125-30
28. Pavlakis SG, Prohovnik I, Piomelli S, et al. 1989. Neurologic complications of sickle cell disease. Adv. Pediatr. 36:247-76
29. Burke GM, Burke AM, Sherma AK, et al. 2009. Moyamoya disease: a summary. Neurosurg. Focus 26(4):E11
30. DeBaun MR, Derdeyn CP, McKinstry RC 3rd. 2006. Etiology of strokes in children with sickle cell anemia. Ment. Retard. Dev. Disabil. Res. Rev. 12(3):192-99
31. Fukui M. 1997. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin. Neurol. Neurosurg. 99(Suppl. 2):S238-40
32. Dobson SR, Holden KR, Nietert PJ, et al. 2002. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99:3144-50
33. Hulbert ML, McKinstry RC, Lacey JL, et al. 2011. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 117(3):772-79
34. Fryer RH, Anderson RC, Chiriboga CA, et al. 2003. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr. Neurol. 29(2):124-30
35. Hankinson TC, Bohman LE, Heyer G, et al. 2008. Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J. Neurosurg. Pediatr. 1(3):211-16
36. Smith ER, McClain CD, Heeney M, et al. 2009. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg. Focus 26(4):E10
37. Walters MC, Hardy K, Edwards S, et al. 2010. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol. Blood Marrow Transplant. 16(2):263-72
38. Hsieh MM, Kang EM, Fitzhugh CD, et al. 2009. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361(24):2309-17
39. Brodsky RA, Luznik L, Bolanos-Meade J, et al. 2008. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 42(8):523-27
40. Leveziel N, Bastuji-Garin S, Lalloum F, et al. 2011. Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine (Baltimore) 90(6):372-78
41. Fox PD, Dunn DT, Morris JS, et al. 1990. Risk factors for proliferative sickle retinopathy. Br. J. Ophthalmol. 74(3):172-76
42. Elagouz M, Jyothi S, Gupta B, et al. 2010. Sickle cell disease and the eye: old and new concepts. Surv. Ophthalmol. 55(4):359-77
43. Mohan JS, Lip PL, Blann AD, et al. 2005. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br. J. Ophthalmol. 89(7):815-19
44. Goldberg MF. 1971. Natural history of untreated proliferative sickle retinopathy. Arch. Ophthalmol. 85(4):428-37
45. Goldberg MF. 1977. Retinal neovascularization in sickle cell retinopathy. Trans. Sect. Ophthalmol. Am. Acad. Ophthalmol. Otolaryngol. 83(3 Pt 1):OP409-31
46. Condon PI, Serjeant GR. 1975. The progression of sickle cell eye disease in Jamaica. Doc. Ophthalmol. 39(1):203-10
47. Kunz Mathews M, McLeod DS, Merges C, et al. 2002. Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy. Br. J. Ophthalmol. 86(6):684-90
48. Condon PI, Serjeant GR. 1980. Behaviour of untreated proliferative sickle retinopathy. Br. J. Ophthalmol. 64(6):404-11
49. Kimmel AS, Magargal LE, Tasman WS. 1986. Proliferative sickle retinopathy and neovascularization of the disc: regression following treatment with peripheral retinal scatter laser photocoagulation. Ophthalmic. Surg. 17(1):20-22
50. Sayag D, Binaghi M, Souied EH, et al. 2008. Retinal photocoagulation for proliferative sickle cell retinopathy: a prospective clinical trial with new sea fan classification. Eur. J. Ophthalmol. 18(2):248-54
51. Downes SM, Hambleton IR, Chuang EL, et al. 2005. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology 112(11):1869-75
52. Lu M, Perez VL, Ma N, et al. 1999. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest. Ophthalmol. Vis. Sci. 40(8):1808-12
53. Barleon B, Sozzani S, Zhou D, et al. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87(8):3336-43
54. Miyamoto K, Khosrof S, Bursell SE, et al. 1999. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. USA 96(19):10836-41
55. Mirshahi A, Roohipoor R, Lashay A, et al. 2008. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur. J. Ophthalmol. 18(2):263-69
56. Anthi A, Machado RF, Jison ML, et al. 2007. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am. J. Respir. Crit. CareMed. 175(12):1272-79
57. Castro O, Hoque M, Brown BD. 2003. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 101(4):1257-61
58. Hassoun PM, Krishnan JA. 2004. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med. 350(24):2521-22
59. Simonneau G, Robbins IM, Beghetti M, et al. 2009. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(1 Suppl.): S43-54
60. Sutton LL, Castro O, Cross DJ, et al. 1994. Pulmonary hypertension in sickle cell disease. Am. J. Cardiol. 74(6):626-28
61. Haque AK, Gokhale S, Rampy BA, et al. 2002. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum. Pathol. 33(10):1037-43
62. Sachdev V, Kato GJ, Gibbs JS, et al. 2011. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in theUnited States and United Kingdom. Circulation 124(13):1452-60
63. Parent F, Bachir D, Inamo J, et al. 2011. A hemodynamic study of pulmonary hypertension in sickle cell disease. N. Engl. J. Med. 365(1):44-53
64. Fonseca GH, Souza R, Salemi VM, et al. 2012. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur. Respir. J. 39(1):112-18
65. Mehari A, Gladwin MT, Tian X, et al. 2012. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 307(12):1254-56
66. McClellan AC, Luthi JC, Lynch JR, et al. 2012. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br. J. Haematol. 159:360-67
67. Graham JK, Mosunjac M, Hanzlick RL, et al. 2007. Sickle cell lung disease and sudden death: a retrospective/prospective stud y of 21 autopsy cases and literature review. Am. J. Forensic Med. Pathol. 28(2):168-72
68. Statius van Eps LW, Schouten H, Haar Romeny-Wachter CC, et al. 1970. The relation between age and renal concentrating capacity in sickle cell disease and hemoglobin C disease. Clin. Chim. Acta 27(3):501-11
69. Van Eps S. 1992. Sickle cell disease and the kidney. In Oxford Textbook of Clinical Nephrology, ed. CS Davison, JP Grunfeld, D Kerr, et al., pp. 700-20. New York: Oxford Univ. Press
70. Van Eps S, de Jong PE. 1988. Sickle cell disease. In Diseases of the Kidney, ed.CWSchrier, RWGottschalk, 2561-2681. Boston: Little, Brown and Company
71. Allon M, Lawson L, Eckman JR, et al. 1988. Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia. Kidney Int. 34(4):500-6
72. de Jong PE, de Jong-Van Den Berg TW, Sewrajsingh GS, et al. 1980. The influence of indomethacin on renal haemodynamics in sickle cell anaemia. Clin. Sci. (Lond.) 59(4):245-50
73. Bank N, Aynedjian HS, Qiu JH, et al. 1996. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 50(1):184-89
74. DeFronzo RA, Taufield PA, Black H, et al. 1979. Impaired renal tubular potassium secretion in sickle cell disease. Ann. Intern. Med. 90(3):310-16
75. Allon M. 1990. Renal abnormalities in sickle cell disease. Arch. Intern. Med. 150(3):501-4
76. Pham PT, Pham PC, Wilkinson AH, et al. 2000. Renal abnormalities in sickle cell disease. Kidney Int. 57(1):1-8
77. de Santis Feltran L, de Abreu Carvalhaes JT, Sesso R. 2002. Renal complications of sickle cell disease: managing for optimal outcomes. Paediatr. Drugs 4(1):29-36
78. Falk RJ, Scheinman J, PhillipsG, et al. 1992. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N. Engl. J. Med. 326(14):910-15
79. Powars DR, Elliott-Mills DD, Chan L, et al. 1991. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann. Intern. Med. 115(8):614-20
80. Devereux S, Knowles SM. 1985. Rhabdomyolysis and acute renal failure in sickle cell anaemia. Br. Med. J. (Clin. Res. Ed.) 290(6483):1707
81. Keeler R, Wilson N. 1989. Natriuretic response to hypervolemia is absent in rats with papillary necrosis. Am. J. Physiol. 257(2 Pt. 2):R422-26
82. Yoshida Y, Fogo A, Ichikawa I. 1989. Glomerular hemodynamic changes versus hypertrophy in experimental glomerular sclerosis. Kidney Int. 35(2):654-60
83. Tejani A, Phadke K, AdamsonO, et al. 1985. Renal lesions in sickle cell nephropathy in children. Nephron 39(4):352-55
84. Falk RJ, Jennette JC. 1994. Sickle cell nephropathy. Adv. Nephrol. Necker Hosp. 23:133-47
85. Ojo AO, Govaerts TC, Schmouder RL, et al. 1999. Renal transplantation in end-stage sickle cell nephropathy. Transplantation 67(2):291-95
86. McPhersonME, Anderson AR, Castillejo MI, et al. 2010. HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease. Pediatr. Blood Cancer 54(4):552-58
87. Buckalew VM Jr, Someren A. 1974. Renal manifestations of sickle cell disease. Arch. Intern. Med. 133(4):660-69
88. Aoki RY, Saad ST. 1995. Enalapril reduces the albuminuria of patients with sickle cell disease. Am. J. Med. 98(5):432-35
89. Foucan L, Bourhis V, Bangou J, et al. 1998. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia. Am. J. Med. 104(4):339-42
90. Platt OS, Orkin SH, Dover G, et al. 1984. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J. Clin. Invest. 74(2):652-56
91. Charache S, Terrin ML, Moore RD, et al. 1995. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med. 332(20):1317-22
92. Wang WC, Ware RE, Miller ST, et al. 2011. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 377(9778):1663-72
93. Charache S, Dover GJ, Moore RD, et al. 1992. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79(10):2555-65
94. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. 2003. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 111(2):231-39
95. Gladwin MT, Shelhamer JH, Ognibene FP, et al. 2002. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br. J. Haematol. 116(2):436-44
96. Hillery CA, Du MC, Wang WC, et al. 2000. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br. J. Haematol. 109(2):322-27
97. Alvarez O, Miller ST, Wang WC, et al. 2012. Effect of hydroxyurea treatment on renal function parameters: results from themulti-center placebo-controlled BABYHUGclinical trial for infants with sickle cell anemia. Pediatr. Blood Cancer 59:668-74
98. McCarville MB, Luo Z, Huang X, et al. 2011. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial. Am. J. Roentgenol. 196(6):1399-404
99. Amin-Hanjani S, Stagliano NE, Yamada M, et al. 2001. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32(4):980-86
100. Asahi M, Huang Z, Thomas S, et al. 2005. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 25(6):722-29
101. Endres M, Laufs U. 2004. Effects of statins on endothelium and signaling mechanisms. Stroke 35(11 Suppl. 1):2708-11
102. Diomede L, Albani D, Sottocorno M, et al. 2001. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler. Thromb. Vasc. Biol. 21(8):1327-32
103. Egashira K, Ni W, Inoue S, et al. 2000. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res. 23(4):353-58
104. Kimura M, Kurose I, Russell J, et al. 1997. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 17(8):1521-26
105. Pruefer D, Scalia R, Lefer AM. 1999. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 19(12):2894-900
106. Sparrow CP, Burton CA, Hernandez M, et al. 2001. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21(1):115-21
107. Cucchiara B, Kasner SE. 2001. Use of statins in CNS disorders. J. Neurol. Sci. 187(1-2):81-89
108. Danesh FR, Kanwar YS. 2004. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 18(7):805-15
109. Feske SK, Sorond FA, Henderson GV, et al. 2009. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res. 1257:89-93
110. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. 1998. Effects of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101(12):2711-19
111. Kureishi Y, Luo Z, Shiojima I, et al. 2000. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6(9):1004-10
112. Yamada M, Huang Z, Dalkara T, et al. 2000. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J. Cereb. Blood Flow Metab. 20(4):709-17